Disease · HP_0012531

Pain

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Pain. Diseases, record HP_0012531. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0012531

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Pain
Open Targets ID: HP_0012531
Other names: Ache, Aches, Burning Pain, Burning Pains, Crushing Pain, Crushing Pains, Migratory Pain, Migratory Pains, Pain, Burning, Pain, Crushing, Pain, Migratory, Pain, Radiating, Pain, Splitting, Pains, Burning, Pains, Crushing, Pains, Migratory, Pains, Radiating, Pains, Splitting, Physical Suffering, Physical Sufferings, Radiating Pain, Radiating Pains, Splitting Pain, Splitting Pains, Suffering, Physical, Sufferings, Physical
Highest stage of its drugs: Approval, for 150 of its 508 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD

Source Open Targets

Drugs508

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ACETAMINOPHEN	CHEMBL112	Small molecule	Approval	ATC, DailyMed, PMDA and TTD	350	105	103	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Approval	DailyMed and PMDA	115	92	87	Drugs and targets
BUPIVACAINE	CHEMBL1098	Small molecule	Approval	DailyMed	91	89	85	Drugs and targets
FENTANYL	CHEMBL596	Small molecule	Approval	ATC, DailyMed, EMA Human Drugs and PMDA	102	74	74	Drugs and targets
MORPHINE	CHEMBL70	Small molecule	Approval	ATC	71	68	68	Drugs and targets
IBUPROFEN	CHEMBL521	Small molecule	Approval	DailyMed and TTD	247	62	61	Drugs and targets
OXYCODONE	CHEMBL656	Small molecule	Approval	ATC, DailyMed and TTD	63	55	55	Drugs and targets
TRAMADOL	CHEMBL1237044	Small molecule	Approval	ATC and TTD	42	40	40	Drugs and targets
HYDROMORPHONE	CHEMBL398707	Small molecule	Approval	ATC and TTD	23	21	21	Drugs and targets
BUPRENORPHINE	CHEMBL511142	Small molecule	Approval	ATC, DailyMed and TTD	23	19	19	Drugs and targets

1 to 10 of 508

See all 508 drugs

Targets207

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
OPRM1	Mu-type opioid receptor	56	Mu opioid receptor agonist; Mu opioid receptor antagonist; Mu opioid receptor partial agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4988	Drugs and targets
PTGS2	Cyclooxygenase	39	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	29	Cyclooxygenase inhibitor; Cyclooxygenase-1 inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
SCN4A	Sodium channel alpha subunit	24	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Approval	https://conductscience.org/library/genes/6329	Drugs and targets
OPRK1	Kappa-type opioid receptor	23	Kappa opioid receptor agonist; Kappa opioid receptor antagonist; Kappa opioid receptor partial agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4986	Drugs and targets
SCN9A	Sodium channel alpha subunit	23	Sodium channel alpha subunit blocker; Sodium channel protein type IX alpha subunit blocker	Approval	https://conductscience.org/library/genes/6335	Drugs and targets
SCN10A	Sodium channel alpha subunit	21	Sodium channel alpha subunit blocker; Sodium channel protein type X alpha subunit blocker	Approval	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	20	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	20	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	20	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6326	Drugs and targets

1 to 10 of 207

See all 207 targets

Trials1,080

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 32 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00699335	Matrifen® for Therapy of Severe Chronic Pain®		5,308	2010-08-12	Severe Chronic Pain	FENTANYL	Its record names the disease	ClinicalTrials.gov
NCT03161093	A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip	Phase 3	3,307	2022-11-14	Osteoarthritis, Knee, Osteoarthritis, Hip	FASINUMAB	Its record names the disease	ClinicalTrials.gov
NCT03304379	Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip	Phase 3	1,650	2023-02-24	Osteoarthritis, Knee, Osteoarthritis, Hip	FASINUMAB	Its record names the disease	ClinicalTrials.gov
NCT00640042	Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza	Phase 4	1,570	2010-02-15	Pain	MORPHINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT03714672	Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction	Phase 3	1,151	2019-07-24	Acute Pain	DICLOFENAC, TRAMADOL	Its record names the disease	ClinicalTrials.gov
NCT05558410	Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty	Phase 3	1,118	2025-07-01	Acute Pain	SUZETRIGINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01358526	Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain	Phase 3	1,095	2014-09-03	Low Back Pain	OXYCODONE	Its record names the disease	ClinicalTrials.gov
NCT01789606	Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet	Phase 3	1,083	2017-08-28	Analgesia	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT05553366	Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy	Phase 3	1,075	2025-08-01	Acute Pain	SUZETRIGINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00486811	A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee	Phase 3	990	2011-01-11	Pain, Knee Osteoarthritis	TAPENTADOL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,080

See all 1,080 trials

Comparisons in its trials353

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Gabapentin vs Placebo: Incidence of Postoperative Delirium by Study Group	84 of 350	72 of 347	697	NCT00221338	Trial comparisons
Gabapentin vs Placebo: deaths from any cause	0 of 350	1 of 347	697	NCT00221338	Trial comparisons
Gabapentin vs Placebo: serious adverse events	31 of 350	44 of 347	697	NCT00221338	Trial comparisons
KPI-121 1% Ophthalmic Suspension vs Vehicle of KPI-121 1% Ophthalmic Suspension: Complete Resolution of Anterior Chamber (AC) Flare at Day 4	113 of 261	63 of 259	520	NCT02793817	Trial comparisons
KPI-121 1% Ophthalmic Suspension vs Vehicle of KPI-121 1% Ophthalmic Suspension: Complete Resolution of Ocular Pain at Day 8	149 of 261	96 of 259	520	NCT02793817	Trial comparisons
KPI-121 1% Ophthalmic Suspension vs Vehicle of KPI-121 1% Ophthalmic Suspension: Complete Resolution of Ocular Pain at Day 4	109 of 261	64 of 259	520	NCT02793817	Trial comparisons
KPI-121 1% Ophthalmic Suspension vs Vehicle of KPI-121 1% Ophthalmic Suspension: deaths from any cause	0 of 261	0 of 259	520	NCT02793817	Trial comparisons
KPI-121 1% Ophthalmic Suspension vs Vehicle of KPI-121 1% Ophthalmic Suspension: Complete Resolution of Anterior Chamber (AC) Cells at Day 8	54 of 261	32 of 259	520	NCT02793817	Trial comparisons
KPI-121 1% Ophthalmic Suspension vs Vehicle of KPI-121 1% Ophthalmic Suspension: serious adverse events	1 of 261	2 of 259	520	NCT02793817	Trial comparisons
OTX-DP vs Placebo Vehicle: deaths from any cause	0 of 216	0 of 221	437	NCT02736175	Trial comparisons

1 to 10 of 353

See all 353 comparisons in its trials

Papers from its trials536

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42032682	RESULT	1	PubMed
39482101	RESULT	1	PubMed
39260540	RESULT	1	PubMed
38836668	RESULT	1	PubMed
38669011	RESULT	1	PubMed
38570229	RESULT	1	PubMed
38044236	RESULT	1	PubMed
36532184	RESULT	1	PubMed
36448276	RESULT	1	PubMed
36044208	RESULT	1	PubMed

1 to 10 of 536

See all 536 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0012531

GET https://conductscience.org/api/diseases/v1/HP_0012531/drugs?page=2

API reference For AI assistants